Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TVTX

Travere Therapeutics Inc

Apr 15 • 04:00PM ET

40.95

-1.18 -2.80 %

Healthcare • Biotechnology • USA • NASD

Apr 14, 8:30 PMFDA full approval of FILSPARI for FSGS triggers 37% share surge.

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: XBI VTI IWM VXF IBB IWO SCHA VTWO PJP FBCG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.60	Insider Own	1.89%	Shs Outstand	90.92M	Perf Week	29.26%
Market Cap	3.78B	Forward P/E	19.27	EPS next Y	2.12	Insider Trans	-32.71%	Shs Float	90.50M	Perf Month	46.09%
Enterprise Value	3.78B	PEG	-	EPS next Q	-0.23	Inst Own	113.38%	Short Float	14.86%	Perf Quarter	40.67%
Income	-50.26M	P/S	7.70	EPS this Y	199.92%	Inst Trans	1.65%	Short Ratio	7.58	Perf Half Y	56.30%
Sales	490.73M	P/B	32.42	EPS next Y	633.31%	ROA	-8.38%	Short Interest	13.45M	Perf YTD	7.17%
Book/sh	1.26	P/C	11.70	EPS next 5Y	-	ROE	-57.80%	52W High	43.31 -5.45%	Perf Year	174.65%
Cash/sh	3.50	P/FCF	99.98	EPS past 3/5Y	49.47% 30.85%	ROIC	-11.48%	52W Low	13.88 195.03%	Perf 3Y	101.53%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	64.89% 19.87%	Gross Margin	85.52%	Volatility	8.82% 5.83%	Perf 5Y	57.86%
Dividend TTM	-	EV/Sales	7.71	EPS Y/Y TTM	86.22%	Oper. Margin	-12.80%	ATR (14)	2.59	Perf 10Y	165.05%
Dividend Ex-Date	-	Quick Ratio	2.70	Sales Y/Y TTM	110.46%	Profit Margin	-10.24%	RSI (14)	72.96	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	2.74	EPS Q/Q	66.42%	SMA20	34.84%	Beta	1.06	Target Price	48.21
Payout	-	Debt/Eq	2.86	Sales Q/Q	73.41%	SMA50	37.91%	Rel Volume	2.60	Prev Close	42.13
Employees	497	LT Debt/Eq	2.81	Earnings	Feb 19 AMC	SMA200	50.17%	Avg Volume	1.77M	Price	40.95
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	1150.00% -10.28%	Trades		Volume	4,523,080	Change	-2.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$49
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30

Show Previous Ratings

Apr-14-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +37.23%
02:06PM	FDA approves first drug for rare kidney scarring disease (Quartz)
09:05AM	Travere Therapeutics Stock Skyrockets On FDA Approval (Investor's Business Daily)
08:07AM	Travere wins long-awaited approval for kidney disease drug (BioPharma Dive)
07:04AM	Travere Therapeutics gains FDA approval for sparsentan in FSGS (Pharmaceutical Business Review)
06:16PM	Loading…
Apr-13-26 06:16PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS (Business Wire) +6.01%
Mar-10-26 12:14PM	VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study (Zacks)
08:02AM	Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) (Insider Monkey)
Feb-24-26 10:18AM	Travere Therapeutics, Inc. (TVTX): A Bull Case Theory (Insider Monkey)
06:50AM	Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 (Insider Monkey)
Feb-20-26 08:30AM	Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
12:03AM	Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-19-26 11:08PM	Travere Therapeutics Q4 Earnings Call Highlights (MarketBeat) +5.13%
05:30PM	Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks)
05:00PM	Loading…
05:00PM	Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss (Investing.com)
04:15PM	Travere: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-18-26 01:10AM	Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market (Insider Monkey)
Feb-17-26 10:00AM	Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-15-26 05:03PM	Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts (MarketBeat)
Feb-12-26 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -9.08%
10:00AM	Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
07:51PM	Loading…
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heerma Peter	CHIEF COMMERCIAL OFFICER	Apr 14 '26	Sale	41.93	7,215	302,516	138,608	Apr 15 09:49 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 15 '26	Sale	41.09	64,000	2,629,975	432,886	Apr 15 09:48 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 14 '26	Option Exercise	17.76	37,500	665,950	156,711	Apr 15 09:47 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 14 '26	Sale	41.21	44,715	1,842,641	111,996	Apr 15 09:47 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 15 '26	Sale	41.83	6,785	283,810	105,211	Apr 15 09:47 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 14 '26	Sale	41.93	7,248	303,892	117,913	Apr 15 09:46 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 15 '26	Sale	42.61	1,014	43,207	116,899	Apr 15 09:46 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 13 '26	Sale	28.85	65	1,875	125,161	Apr 15 09:46 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Apr 14 '26	Sale	41.93	7,215	302,516	112,491	Apr 15 09:46 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Apr 15 '26	Sale	42.61	1,018	43,377	111,473	Apr 15 09:46 PM
Dube Eric M	Officer	Apr 15 '26	Proposed Sale	41.09	64,000	2,629,833		Apr 15 04:16 PM
ELIZABETH REED	Officer	Apr 15 '26	Proposed Sale	41.83	6,785	283,823		Apr 15 04:15 PM
CHRISTOPHER CLINE	Officer	Apr 15 '26	Proposed Sale	42.61	1,014	43,207		Apr 15 04:14 PM
JULA INRIG	Officer	Apr 15 '26	Proposed Sale	42.61	1,018	43,377		Apr 15 04:13 PM
Elizabeth E. Reed	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 09:17 PM
Jula Inrig	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 08:53 PM
Peter Heerma	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 08:47 PM
Christopher Cline	Officer	Apr 14 '26	Proposed Sale	41.93	7,239	303,522		Apr 14 08:40 PM
GARY A LYONS	Officer	Apr 14 '26	Proposed Sale	30.70	8,000	245,600		Apr 14 04:27 PM
CHRISTOPHER CLINE	Officer	Apr 14 '26	Proposed Sale	41.07	9	370		Apr 14 04:20 PM
ELIZABETH REED	Officer	Apr 14 '26	Proposed Sale	41.07	37,500	1,540,125		Apr 14 04:19 PM
ROY BAYNES	Director	Apr 14 '26	Proposed Sale	41.29	32,750	1,352,130		Apr 14 04:09 PM
SANDRA CALVIN	Officer	Apr 14 '26	Proposed Sale	41.07	21,977	902,595		Apr 14 04:02 PM
Christopher Cline	Officer	Apr 13 '26	Proposed Sale	28.85	65	1,875		Apr 13 08:11 PM
Baynes Roy D.	Director	Apr 06 '26	Option Exercise	26.52	10,000	265,200	47,500	Apr 07 06:17 PM
Baynes Roy D.	Director	Apr 06 '26	Sale	33.00	10,000	330,000	37,500	Apr 07 06:17 PM
ROY BAYNES	Director	Apr 06 '26	Proposed Sale	33.00	10,000	330,000		Apr 06 04:06 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 01 '26	Option Exercise	15.46	60,000	927,600	492,886	Apr 02 05:55 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 01 '26	Sale	30.93	60,000	1,855,839	432,886	Apr 02 05:55 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 01 '26	Option Exercise	15.46	10,000	154,600	115,211	Apr 02 05:55 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 01 '26	Sale	30.00	10,000	300,000	105,211	Apr 02 05:55 PM
Dube Eric M	Officer	Apr 01 '26	Proposed Sale	30.93	60,000	1,855,655		Apr 01 04:13 PM
ELIZABETH REED	Officer	Apr 01 '26	Proposed Sale	30.00	10,000	300,000		Apr 01 04:06 PM
REED ELIZABETH E	Chief Legal Officer and GC	Mar 16 '26	Option Exercise	19.08	10,000	190,800	115,211	Mar 18 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Mar 16 '26	Sale	28.09	10,000	280,861	105,211	Mar 18 04:05 PM
ELIZABETH REED	Officer	Mar 16 '26	Proposed Sale	28.09	10,000	280,861		Mar 16 04:20 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 20 '26	Option Exercise	15.46	60,000	927,600	492,886	Feb 24 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 20 '26	Sale	30.10	60,000	1,805,766	432,886	Feb 24 04:05 PM
Dube Eric M	Officer	Feb 20 '26	Proposed Sale	30.10	60,000	1,805,766		Feb 20 04:49 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 17 '26	Option Exercise	19.08	10,000	190,800	115,211	Feb 19 04:10 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 17 '26	Sale	27.83	10,000	278,315	105,211	Feb 19 04:10 PM
ELIZABETH REED	Officer	Feb 17 '26	Proposed Sale	27.83	10,000	278,317		Feb 17 04:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '26	Sale	32.21	1,779	57,295	105,706	Feb 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	32.19	1,745	56,168	111,226	Feb 05 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 04 '26	Sale	32.18	2,994	96,359	105,211	Feb 05 04:05 PM
ELIZABETH REED	Officer	Feb 04 '26	Proposed Sale	32.18	2,994	96,360		Feb 04 04:07 PM
JULA INRIG	Officer	Feb 04 '26	Proposed Sale	32.21	1,779	57,299		Feb 04 04:06 PM
CHRISTOPHER CLINE	Officer	Feb 04 '26	Proposed Sale	32.19	1,745	56,166		Feb 04 04:01 PM
Peter Heerma	Officer	Feb 03 '26	Proposed Sale	32.12	7,310	234,799		Feb 04 06:00 AM
Elizabeth E. Reed	Officer	Feb 03 '26	Proposed Sale	32.12	7,175	230,464		Feb 03 09:59 PM
Sandra Calvin	Officer	Feb 03 '26	Proposed Sale	32.12	4,333	139,177		Feb 03 09:58 PM
Christopher Cline	Officer	Feb 03 '26	Proposed Sale	32.12	7,242	232,616		Feb 03 09:45 PM
Jula Inrig	Officer	Feb 03 '26	Proposed Sale	32.12	6,956	223,429		Feb 03 09:37 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '26	Sale	32.28	100,087	3,230,316	432,886	Feb 03 09:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '26	Sale	32.12	6,956	223,427	107,485	Feb 03 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	32.12	7,242	232,613	112,971	Feb 03 09:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '26	Sale	32.12	7,310	234,797	131,823	Feb 03 09:30 PM
ROTE WILLIAM E.	Chief Research Officer	Feb 03 '26	Sale	32.87	12,446	409,100	109,087	Feb 03 09:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '26	Sale	32.12	4,333	139,176	49,080	Feb 03 09:30 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 03 '26	Sale	32.12	7,175	230,461	108,205	Feb 03 09:30 PM
Dube Eric M	Officer	Feb 03 '26	Proposed Sale	32.87	100,087	3,289,860		Feb 03 11:38 AM
ROTE WILLIAM E.	Officer	Feb 03 '26	Proposed Sale	32.87	12,446	409,100		Feb 03 10:05 AM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Option Exercise	15.46	51,865	801,833	471,038	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Option Exercise	15.46	8,135	125,767	427,308	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Sale	30.10	51,865	1,560,981	419,173	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Sale	30.01	8,135	244,153	419,173	Jan 27 08:25 PM
Dube Eric M	Officer	Jan 27 '26	Proposed Sale	30.10	51,865	1,560,982		Jan 27 04:05 PM
Dube Eric M	Officer	Jan 23 '26	Proposed Sale	30.01	8,135	244,153		Jan 23 04:14 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Option Exercise	19.08	10,000	190,800	100,270	Jan 21 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Sale	27.34	10,000	273,420	90,270	Jan 21 04:05 PM
ELIZABETH REED	Officer	Jan 20 '26	Proposed Sale	27.34	10,000	273,420		Jan 20 04:04 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 05 '26	Sale	40.18	2,031	81,606	86,756	Jan 07 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	37.75	445	16,799	86,311	Jan 07 04:05 PM
JULA INRIG	Officer	Jan 06 '26	Proposed Sale	37.75	445	16,799		Jan 06 04:07 PM
Jula Inrig	Officer	Jan 05 '26	Proposed Sale	40.18	2,031	81,606		Jan 05 07:49 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Dec 24 '25	Sale	40.00	4,980	199,200	113,013	Dec 29 09:11 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Option Exercise	20.61	60,000	1,236,600	161,443	Dec 29 09:05 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Sale	40.10	60,000	2,406,180	101,443	Dec 29 09:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Option Exercise	8.93	15,000	133,950	103,787	Dec 29 09:01 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Sale	42.00	15,000	630,004	88,787	Dec 29 09:01 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 24 '25	Sale	40.00	7,402	296,080	38,233	Dec 29 08:59 PM
JULA INRIG	Officer	Dec 24 '25	Proposed Sale	42.00	15,000	630,004		Dec 29 09:39 AM
SANDRA CALVIN	Officer	Dec 24 '25	Proposed Sale	40.00	7,402	296,080		Dec 29 09:38 AM
Heerma Peter	Officer	Dec 24 '25	Proposed Sale	40.00	4,980	199,200		Dec 29 06:58 AM
ROTE WILLIAM E.	Officer	Dec 24 '25	Proposed Sale	40.10	60,000	2,406,179		Dec 29 06:28 AM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 15 '25	Sale	36.00	2,910	104,760	45,635	Dec 16 04:23 PM
SANDRA CALVIN	Officer	Dec 15 '25	Proposed Sale	36.00	2,910	104,760		Dec 15 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	16.23	20,000	324,600	112,083	Dec 03 04:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	35.01	20,000	700,202	92,083	Dec 03 04:30 PM
CHRISTOPHER CLINE	Officer	Dec 01 '25	Proposed Sale	35.01	20,000	700,200		Dec 01 04:09 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Option Exercise	24.02	61,250	1,471,212	115,660	Nov 06 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Sale	36.00	67,115	2,416,140	48,545	Nov 06 04:05 PM
SANDRA CALVIN	Officer	Nov 04 '25	Proposed Sale	36.00	67,115	2,416,140		Nov 04 04:14 PM
Coughlin Timothy	Director	Oct 31 '25	Option Exercise	16.95	18,000	305,040	73,500	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Sale	35.03	18,000	630,601	55,500	Nov 04 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 31 '25	Sale	35.00	5,591	195,685	119,071	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Proposed Sale	34.98	18,000	629,693		Oct 31 04:05 PM
Heerma Peter	Officer	Oct 31 '25	Proposed Sale	35.00	5,591	195,685		Oct 31 02:51 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Option Exercise	15.46	92,872	1,435,801	512,045	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	15.46	27,128	419,399	446,301	Oct 30 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVTX

Travere Therapeutics Inc

Upgrade your Finviz experience